CONMED Corporation (CNMD) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CNMD, 37.34$ (piyasa değeri $1.16B) fiyatla Healthcare işi olan CONMED Corporation'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 46/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 9 Şub 2026CONMED Corporation (CNMD) Sağlık ve Boru Hattı Genel Bakışı
CONMED Corporation (CNMD) offers a notable research candidate within the medical device sector, driven by its innovative surgical solutions, established market presence, and a focus on minimally invasive procedures, positioning it for sustained growth and shareholder value with a current dividend yield of 1.93%.
Yatırım Tezi
CONMED presents a notable research candidate driven by its diversified product portfolio, established market presence, and focus on innovative surgical solutions. The company's orthopedic and general surgery segments are poised for growth, fueled by increasing demand for minimally invasive procedures and an aging global population. With a P/E ratio of 27.33 and a dividend yield of 1.93%, CONMED offers a blend of value and income potential. Key growth catalysts include the expansion of its product offerings, strategic acquisitions, and penetration into emerging markets. The company's commitment to research and development, coupled with its direct sales and distribution network, positions it for sustained revenue growth and enhanced profitability. Investors may want to evaluate CONMED for its long-term growth prospects and potential for shareholder value creation.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $1.29 billion, reflecting a solid market valuation.
- P/E ratio of 27.33, indicating investor confidence in future earnings potential.
- Profit margin of 3.4%, demonstrating profitability in a competitive market.
- Gross margin of 53.9%, showcasing efficient cost management and pricing strategies.
- Dividend yield of 1.93%, providing a steady income stream for investors.
Rakipler & Benzerleri
Güçlü Yönler
- Diversified product portfolio across orthopedic and general surgery.
- Established market presence and brand reputation.
- Direct sales and distribution network.
- Focus on innovation and development of advanced surgical solutions.
Zayıflıklar
- Relatively low profit margin compared to some competitors.
- Dependence on third-party distributors in certain markets.
- Exposure to regulatory risks and compliance requirements.
- Potential for product liability claims.
Katalizörler
- Upcoming: New product launches in the orthopedic surgery segment, expected to drive revenue growth.
- Ongoing: Expansion of direct sales force in key geographic markets, enhancing market penetration.
- Ongoing: Strategic partnerships with hospitals and healthcare institutions, securing long-term contracts.
- Upcoming: Regulatory approvals for new medical devices, expanding product offerings.
Riskler
- Potential: Product recalls or safety concerns, impacting brand reputation and sales.
- Potential: Increased competition from lower-cost manufacturers, eroding market share.
- Ongoing: Fluctuations in foreign exchange rates, affecting international sales.
- Ongoing: Changes in healthcare regulations and reimbursement policies, impacting profitability.
Büyüme Fırsatları
- Expansion of Orthopedic Surgery Products: CONMED can capitalize on the growing demand for advanced orthopedic solutions by expanding its TruShot, Y-knot, and PopLok product lines. The global orthopedic devices market is projected to reach $60 billion by 2028, offering significant growth potential. CONMED's focus on minimally invasive techniques and innovative designs provides a competitive edge in this market.
- Penetration into Emerging Markets: Emerging markets, such as China and India, present substantial growth opportunities for CONMED. These regions are experiencing rapid growth in healthcare expenditure and increasing adoption of advanced medical technologies. By establishing strategic partnerships and tailoring its product offerings to local needs, CONMED can gain a significant foothold in these high-growth markets.
- Strategic Acquisitions: CONMED can pursue strategic acquisitions to expand its product portfolio and market reach. Acquiring companies with complementary technologies or established distribution networks can accelerate growth and enhance CONMED's competitive position. The company's strong financial position enables it to pursue accretive acquisitions that generate long-term value for shareholders.
- Development of Endoscopic Technologies: CONMED can further develop its endoscopic technologies for use in gastroenterology procedures and treatments for biliary structure diseases. The global endoscopy market is projected to reach $40 billion by 2027, driven by increasing demand for minimally invasive diagnostic and therapeutic procedures. CONMED's expertise in this area positions it to capture a significant share of this growing market.
- Enhancement of Cardiac Monitoring Products: CONMED can enhance its cardiac monitoring product line, including ECG and EEG electrodes, and cardiac defibrillation pads. The global cardiac monitoring market is projected to reach $30 billion by 2028, driven by the increasing prevalence of cardiovascular diseases and the growing adoption of remote monitoring technologies. CONMED's focus on innovation and product quality can drive growth in this market.
Fırsatlar
- Expansion into emerging markets with high growth potential.
- Strategic acquisitions to expand product portfolio and market reach.
- Development of new and innovative surgical solutions.
- Increased adoption of minimally invasive surgical procedures.
Tehditler
- Intense competition from established medical device companies.
- Pricing pressures from hospitals and healthcare providers.
- Technological obsolescence and the need for continuous innovation.
- Economic downturns and reduced healthcare spending.
Rekabet Avantajları
- Established brand reputation in the surgical device market.
- Diversified product portfolio catering to multiple surgical specialties.
- Direct sales and distribution network providing a competitive advantage.
- Focus on innovation and development of advanced surgical solutions.
CNMD Hakkında
CONMED Corporation, established in 1970 and headquartered in Largo, Florida, is a global medical technology company specializing in the development, manufacturing, and sale of surgical devices and related equipment. The company's comprehensive portfolio caters to a broad range of surgical procedures, with a strong emphasis on orthopedic and general surgery. CONMED's orthopedic surgery products include the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, providing surgeons with advanced solutions for soft tissue repair and minimally invasive sports medicine surgeries. These products are marketed under the Hall, CONMED Linvatec, Concept, and Shutt brands. In general surgery, CONMED offers a diverse range of products, including clinical insufflation, smoke evacuation, electrosurgical, and endomechanical devices. Furthermore, the company provides endoscopic technologies for gastroenterology procedures and treatments for biliary structure diseases, along with cardiac monitoring products like ECG and EEG electrodes, and cardiac defibrillation pads. CONMED distributes its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors, ensuring widespread market access. With a market capitalization of $1.29 billion, CONMED continues to strengthen its position as a key player in the global medical device industry.
Ne Yaparlar
- Develops and manufactures surgical devices.
- Offers orthopedic surgery products for soft tissue repair.
- Provides general surgery products, including electrosurgical devices.
- Offers endoscopic technologies for gastroenterology procedures.
- Manufactures cardiac monitoring products, such as ECG electrodes.
- Sells products directly to hospitals and surgery centers.
- Distributes products through medical specialty distributors.
İş Modeli
- Develops and manufactures surgical devices and equipment.
- Sells products directly to hospitals, surgery centers, and healthcare institutions.
- Utilizes medical specialty distributors to expand market reach.
- Generates revenue through product sales and related services.
Sektör Bağlamı
CONMED operates within the medical device industry, a sector characterized by continuous innovation, increasing regulatory scrutiny, and evolving patient needs. The global medical device market is projected to reach trillions of dollars by 2026, driven by technological advancements, an aging population, and rising healthcare expenditure. CONMED competes with other medical device companies such as AZTA, AHCO, ESTA, INMD, and KMTS. CONMED's focus on minimally invasive surgical solutions and its diversified product portfolio positions it favorably within this competitive landscape. The company's direct sales and distribution network provides a strategic advantage in reaching key customer segments.
Kilit Müşteriler
- Hospitals
- Surgery centers
- Healthcare institutions
- Medical specialty distributors
Finansallar
Grafik & Bilgi
CONMED Corporation (CNMD) hisse senedi fiyatı: $37.34 (+0.00, +0.00%)
Son Haberler
-
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
StockStory · 6 Mar 2026
-
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Yahoo! Finance: CNMD News · 10 Şub 2026
-
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Zacks · 10 Şub 2026
-
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
zacks.com · 10 Şub 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CNMD için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CNMD için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CNMD'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD Healthcare Hisse Senedi SSS
CNMD için değerlendirilmesi gereken temel faktörler nelerdir?
CONMED Corporation (CNMD) şu anda yapay zeka skoru 46/100, düşük puanı gösteriyor. Hisse 30.3x F/K oranıyla işlem görüyor, S&P 500 ortalamasına (~20-25x) yakın. Temel güçlü yan: Diversified product portfolio across orthopedic and general surgery.. İzlenmesi gereken birincil risk: Potential: Product recalls or safety concerns, impacting brand reputation and sales.. Bu bir finansal tavsiye değildir.
CNMD MoonshotScore'u nedir?
CNMD şu anda MoonshotScore'da 46/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CNMD verileri ne sıklıkla güncellenir?
CNMD fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CNMD hakkında ne diyor?
CNMD için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CNMD'a yatırım yapmanın riskleri nelerdir?
CNMD için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Product recalls or safety concerns, impacting brand reputation and sales.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CNMD'ın P/E oranı nedir?
CONMED Corporation (CNMD)'nın son P/E oranı 30.3, ki bu da orta bir aralıkta. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
CNMD aşırı değerli mi, yoksa düşük değerli mi?
CONMED Corporation (CNMD)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 30.3. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CNMD'ın temettü verimi nedir?
CONMED Corporation (CNMD) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the most recent available information.
- Market projections are based on industry reports and analyst estimates.
- This analysis is for informational purposes only and does not constitute investment advice.